PULSE › Topics › Lp(A)
Lp(A)
4 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
Two late-stage heart-disease medicines have failed to deliver expected cardiovascular benefits despite promising biomarker improvements, raising questions about how drug developers measure success.
2 sources
2 articles
v 1
8d ago
◼ Archived
Business
🔮 fades ✓
Novartis experiences a trial failure with pelacarsen, impacting the Dow and raising questions for competitors like Amgen and Lilly.
1 sources
1 articles
v 1
70d ago
◼ Archived
Business
🔮 fades ✗
A failed Novartis clinical trial for a cholesterol drug has triggered a biopharma selloff and cast doubt on competing efforts by Amgen and Eli Lilly.
3 sources
4 articles
v 2
70d ago
◼ Archived
Business
🔮 fades ✗
Novartis and Ionis face setbacks as a high-stakes Phase 3 trial for an Lp(a) cardiovascular drug fails to meet its primary goals.
2 sources
2 articles
v 1
72d ago
\n
\n
\n